Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about EWTX, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| EDG-15400 | Heart Failure With Preserved Ejection Fraction | Phase 2 · NCT07795814 | Recruiting |
| Sevasemten Dose 5 | Duchenne Muscular Dystrophy | Phase 2 · NCT05540860 | Active not recruiting |
| Sevasemten Dose 4 | Duchenne Muscular Dystrophy | Phase 2 · NCT05540860 | Active not recruiting |
| EDG-7500 | Hypertrophic Cardiomyopathy | Phase 2 · NCT06347159 | Active not recruiting |
| Sevasemten Dose 3 | Duchenne Muscular Dystrophy | Phase 2 · NCT06100887 | Active not recruiting |
| Sevasemten Dose 2 | Duchenne Muscular Dystrophy | Phase 2 · NCT06100887 | Active not recruiting |
| Sevasemten | Becker Muscular Dystrophy | Phase 2 · NCT06066580 | Enrolling by invitation |
| Sevasemten Dose 1 | Duchenne Muscular Dystrophy | Phase 2 · NCT06100887 | Active not recruiting |
| Verapamil | Healthy Subjects | Phase 1 · NCT06916897 | Completed |
| [14C]-EDG-7500 | Healthy Volunteer | Phase 1 · NCT06738836 | Completed |
| Radiolabeled EDG-5506 Suspension | Healthy Volunteer | Phase 1 · NCT05730842 | Completed |
| Radiolabeled EDG-5506 Intravenous | Healthy Volunteer | Phase 1 · NCT05730842 | Completed |
| EDG-5506 | Healthy Volunteer | Phase 1 · NCT05730842 | Completed |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
EWTX holds $460.7M in cash and short-term investments (as of Jun 30, 2026) and burns about $42.5M/quarter from operations, an estimated runway of 32.5 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 25 · Moderate
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when EWTX files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| ORBIMED ADVISORS LLC Director, 10% owner |
Insider | 15,252,867 | 14.04% | 2025-05-09 |
| Paradigm BioCapital Advisors LP | Institution (13G, 5%+) | 10,215,455 | 9.41% | 2026-06-30 |
| RA Capital Management, L.P. | Institution (13G, 5%+) | 8,392,730 | 7.73% | 2026-06-30 |
| Blackrock Inc. | Institution (13F) | 6,606,336 | 6.08% | 2026-06-30 |
| Jupiter Topco LLC | Institution (13F) | 6,075,331 | 5.59% | 2026-06-30 |
| JANUS HENDERSON GROUP PLC | Institution (13G, 5%+) | 5,915,556 | 5.45% | 2026-03-31 |
| FMR LLC | Institution (13G, 5%+) | 5,489,135 | 5.05% | 2026-06-30 |
| Novo Holdings A/S | Institution (13F) | 5,350,000 | 4.93% | 2026-06-30 |
| Driehaus Capital Management, LLC | Institution (13F) | 4,728,623 | 4.35% | 2026-06-30 |
| Perceptive Advisors Llc | Institution (13F) | 4,373,974 | 4.03% | 2026-06-30 |
| Vanguard Capital Management LLC | Institution (13F) | 3,860,670 | 3.55% | 2026-06-30 |
| Peter A. Thompson Director, 10% owner · +46,377 options |
Insider | 443,792 | 0.41% | 2025-04-03 |
Share count 108,604,129 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-06-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-08-12 filed 2026-08-17 |
Russell Alan J |
Option award (A) | 65,000 | – | – |
| 2026-08-12 filed 2026-08-17 |
Derakhshan Behrad |
Option award (A) | 100,000 | – | – |
| 2026-08-12 filed 2026-08-17 |
Nofi Michael |
Option award (A) | 48,750 | – | – |
| 2026-08-12 filed 2026-08-17 |
Donovan Joanne M. |
Option award (A) | 65,000 | – | – |
| 2026-08-12 filed 2026-08-17 |
MOORE JOHN R |
Option award (A) | 65,000 | – | – |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for EWTX and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →